Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Genitourinary 1

Conditions

Breast Neoplasms 2Ovarian Neoplasms 1Neuralgia 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 266Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 146Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Telmisartan × Breast × Clear all
NCT07370506 2026-01-29

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Tanta University

Phase 1/2 Not yet recruiting
36 enrolled
Breast

Breast Neoplasms

NCT05322889 2024-08-28

PrevTel

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP

Phase 2 Completed
35 enrolled
BreastGynecologic

Breast Neoplasms, Neuralgia, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡